Triple-Negative Breast Cancer: Why Your “Baseline” ctDNA Level May Be the Most Important Number You Haven’t Been Told

March 11, 2026

| Edited By: Sripriya Nayak

In this Article

Some links in this article are affiliate links. We may earn a small commission if you make a purchase through these links, at no extra cost to you. We only recommend products we find useful to our readers

Triple-negative breast cancer (TNBC) is often discussed in terms of aggressive biology, fewer targeted therapies, and higher recurrence risk than other breast cancer types. Patients are told about tumor size, lymph node involvement, grade, and response to chemotherapy. These are standard numbers.

But there is one number that is quietly entering serious clinical research discussions, and many patients never hear about it at all: Your baseline ctDNA level.

Not after treatment. Not months later. Baseline means the amount of tumor DNA detectable in blood before therapy begins.

This is not a routine test yet. But the reason for its popularity is simple: Baseline ctDNA may reflect the real hidden burden of disease better than scans or pathology alone.

And for TNBC, that matters more than ever.

What Is ctDNA, and Why Does It Matter in Breast Cancer?

ctDNA stands for circulating tumor DNA.

When cancer cells grow and die, they release tiny fragments of DNA into the bloodstream. These fragments carry tumor-specific genetic changes. Modern blood-based tests can detect them, sometimes at extremely low levels.

So instead of looking at cancer through imaging or surgery alone, ctDNA offers a different lens:

Not what is visible
Not what was removed
But what may still be biologically active in the body

It is sometimes called a “liquid biopsy” (a blood test used instead of tissue surgery), but that term can sound too casual. In reality, ctDNA is not just another test; it is a way of measuring cancer presence at the molecular level.

In breast cancer, ctDNA is being studied for:

Detecting minimal residual disease (MRD) (small leftover cancer cells that scans can’t see)
Predicting relapse before symptoms
Monitoring treatment response in real time
Risk stratification (sorting patients by how high or low their risk is) beyond traditional staging

But one part is getting special attention in TNBC: Baseline ctDNA.

Understanding Triple-Negative Breast Cancer (TNBC)

Triple-negative breast cancer is defined by what it lacks: No estrogen receptor (ER), no progesterone receptor (PR), and no HER2 amplification.
That means hormonal therapies and HER2-targeted drugs don’t work here.

TNBC is also known for:

Faster growth
Higher early recurrence risk (especially in the first 3–5 years)
Strong reliance on chemotherapy and immunotherapy
High importance of achieving pathological complete response (pCR) (no cancer found after treatment and surgery)

But TNBC is not one disease. It is biologically diverse. Some tumors respond beautifully to therapy. Others relapse even after “good” initial treatment.

The big question is: Can we identify who is truly at high risk before starting therapy? Baseline ctDNA might help.

Why Your “Baseline” ctDNA Level Matters Most

1. What “Baseline” ctDNA Actually Means

Baseline ctDNA refers to the ctDNA detected before any treatment begins, usually before neoadjuvant chemotherapy (chemo given before surgery). It is like taking a molecular snapshot (a DNA-based picture of cancer at one moment) of cancer activity at time zero.

This matters because baseline ctDNA is not only about tumor size. It may reflect: Tumor shedding into blood, microscopic spread not visible on imaging, biological aggressiveness, and hidden disease burden.

Two patients can have the same stage on paper but different baseline ctDNA levels, suggesting different underlying realities.

That is why baseline is being explored as a risk marker, not just a diagnostic tool.

2. Baseline ctDNA as a Predictor of Treatment Response

One of the most practical questions in TNBC is: Will chemotherapy work well for this tumor?

Currently, we wait until surgery to know if pCR was achieved. But baseline ctDNA may give early clues. Research is showing that patients with: Higher baseline ctDNA levels often have a lower chance of achieving a complete response.

This is not because chemo cannot work, but because baseline ctDNA may reflect more systemic (whole body) disease potential, higher tumor turnover, and greater genomic instability (cancer DNA that mutates and changes easily).

In simple terms: Baseline ctDNA may tell us who needs more aggressive or adaptive strategies from day one. That is a major shift.

3. The Link Between Baseline ctDNA and Recurrence Risk

Recurrence in TNBC is feared because it often happens early and can be aggressive.

Baseline ctDNA is being studied as an early predictor of recurrence because it may indicate:

Cancer cells already circulating
Early micrometastatic disease (very tiny cancer spread not visible on scans)
Higher molecular disease burden (how much cancer exists at the DNA level, not on scans) even in “localized” cancer

What is striking is that baseline ctDNA sometimes correlates with outcomes even when the tumor appears operable, nodes are negative, and imaging is clean.

So baseline ctDNA could become a marker of “molecular stage” (risk assessment based on DNA signals instead of size), not just anatomical stage (staging based on tumor size and lymph nodes). This is where the field is moving.

What Recent Research Reveals About ctDNA in Early-Stage TNBC

1. Key Prospective Trials

Several prospective studies have explored ctDNA in early breast cancer, including TNBC subsets.

Common findings include:

ctDNA is detectable in a significant proportion of early TNBC patients at baseline
Clearance of ctDNA during therapy correlates with better outcomes
Persistent ctDNA after treatment predicts relapse months before imaging

Some major research directions include ctDNA-guided escalation trials, MRD detection after neoadjuvant therapy, and combining ctDNA with immune response markers (signals showing how the immune system reacts to cancer).

Even though different platforms are used, the signal is consistent: ctDNA is not just prognostic after treatment; baseline levels already carry meaning.

2. What These Results Mean Clinically

Clinically, baseline ctDNA could eventually help answer:

Who needs intensified neoadjuvant regimens?
Who might benefit from additional immunotherapy?
Who should be followed more closely post-treatment?
Who may be eligible for MRD-based trials?

But right now, it is still mostly research-driven. We are at the “evidence-building” stage, not full implementation. That distinction is important for patients.

Current Barriers and What’s Next for ctDNA Testing

1. Sensitivity and Technical Limitations

ctDNA detection is not perfect. Early-stage tumors may shed very low DNA levels, leading to false negatives (the test says “no cancer DNA” when some may still be there).

Also, assay sensitivity (how good a test is at detecting very small amounts) varies:

Tumor-informed tests (a blood test customized to tumor mutations) are more sensitive
Tumor-agnostic panels may miss low-level disease (a general cancer DNA test not tailored to your tumor)

Dr. Enriqueta Felip, MD, PhD, of Vall d’Hebron Institute of Oncology, has noted that so-called tumor-informed assays require sequencing of tumor tissue to identify trackable mutations, which increases turnaround time, and that approximately one in five patients lacks sufficient tumor tissue for analysis.

So baseline ctDNA is informative but not absolute.

2. Timing and Frequency of Testing

Baseline is only the beginning. The real power may come from serial testing: before treatment, mid-therapy, after surgery, or during follow-up.

But questions remain: How often should it be done? What threshold defines high risk? What actions should follow a positive result?
Without clear protocols, routine use is limited.

3. Not Yet Standard of Care, But Getting Closer

At present, ctDNA testing is not standard for early-stage TNBC. Most guidelines do not recommend it routinely outside trials. Clinical decisions are still based on stage, pCR, and pathology.

Dr. Jordi Remon Masip, MD, PhD, of Gustave Roussy in Villejuif, France, said that while MRD appears to identify a high-risk population, its role in guiding treatment decisions remains uncertain and requires prospective trials.

However, ctDNA is moving fast, and baseline measurement may become part of future TNBC stratification models.

The direction is clear: From imaging-based oncology → to molecular oncology.

What Patients Should Know About Their ctDNA Results

If you are a patient hearing about ctDNA, here are realistic points:

A positive baseline ctDNA does not mean metastatic cancer
A negative ctDNA does not guarantee zero risk
Baseline ctDNA is a risk signal, not a verdict
It is best interpreted with stage, response, and clinical context
If available, it may open doors to clinical trials and closer monitoring

Final Thoughts

Baseline ctDNA is not yet a routine number on your pathology report. But in TNBC, it may become one of the most meaningful early markers we have.

TNBC is not only about what we can remove surgically; it is also about what might already be biologically active beyond what scans show.

Baseline ctDNA represents an early molecular signal of disease burden, of treatment sensitivity, and of recurrence risk.

The future of TNBC care may not start after chemotherapy or surgery. It may start with what the blood reveals before anything begins.

Key Takeaways

Baseline ctDNA may reflect hidden disease burden, even when imaging looks localized.
High baseline ctDNA could identify biologically high-risk TNBC early, before treatment response is known.
Baseline ctDNA appears to act as a biological resistance marker rather than merely a disease-volume marker.
Current evidence is strong but not standardized, and ctDNA is still mainly used in research settings.
Major research gap: We still lack clear clinical protocols on what exact treatment changes should follow a positive baseline ctDNA result.

FAQs

1. Is baseline ctDNA testing routine for TNBC patients today?

No, it is mostly used in clinical trials or specialized centers.

2. Does a positive baseline ctDNA mean cancer has spread?

Not necessarily. It may indicate higher tumor DNA shedding, not confirmed metastasis.

3. Can ctDNA replace scans?

Not currently. ctDNA complements imaging but does not replace it.

4. How early can ctDNA detect relapse?

ctDNA may become positive up to 6–10 months before radiologic recurrence.

5. Should patients request baseline ctDNA testing now?

It can be discussed, especially in centers running clinical trials. However, decisions should not yet be based solely on this test.

References